



## Mechanisms of Melanoma Progression

Guest Editor:

**Dr. Mohamed Hassan**

1. Research Laboratory of Surgery-Oncology, Department of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA
2. Institut National de la Santé et de la Recherche Médicale, S1121, University of Strasbourg, 67000 Strasbourg, France

Deadline for manuscript submissions:

**closed (1 May 2024)**

### Message from the Guest Editor

Dear Colleagues,

Melanoma progression, metastasis and drug resistance are not only driven by irreversible genetic instability, but also by reversible and functional reprogramming of signaling routes. PI3K, together with downstream dependent and/or converged routes, is able to mediate extra- or intra-transduction signals, leading to the initiation of tumor development, progression and resistance.

The aim of this Special Issue is to update the current findings addressing the role of receptor and non-receptor tyrosine kinases in melanoma progression and treatment resistance.

Dr. Mohamed Hassan  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

**Prof. Dr. Samuel C. Mok**

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)